These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2081281)

  • 21. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase.
    Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G
    Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J; de Torres Mateos JA
    Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M; Yonese J; Fukui I; Ogata E
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum tumor markers in skeletal metastasis.
    Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
    Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases.
    Ritzke C; Stieber P; Untch M; Nagel D; Eiermann W; Fateh-Moghadam A
    Anticancer Res; 1998; 18(2B):1243-9. PubMed ID: 9615795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.
    Voorzanger-Rousselot N; Journe F; Doriath V; Body JJ; Garnero P
    Calcif Tissue Int; 2009 May; 84(5):348-54. PubMed ID: 19252761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of urinary hydroxyproline and bone isoenzyme of alkaline phosphatase in the early detection and follow-up of bone metastasis in breast cancer patients.
    Frenay M; Namer M; Boublil JL; Khater R; Viot M; François E; Milano G
    Bull Cancer; 1988; 75(6):533-9. PubMed ID: 3416085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M
    Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical markers for assessment of bone metastases in patients with breast cancer.
    Hou MF; Tsai LY; Tsai SM; Huang CJ; Huang YS; Hsieh JS; Chan HM; Wang JY; Chuang CH; Chen FM; Huang TJ
    Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acid phosphatase (ACP)].
    Igawa M; Kishi H; Ishibe T
    Nihon Rinsho; 1995 May; 53(5):1203-8. PubMed ID: 7602779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.
    Ramankulov A; Lein M; Kristiansen G; Loening SA; Jung K
    Prostate; 2007 Feb; 67(3):330-40. PubMed ID: 17192877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
    Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
    Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
    Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme patterns in cancer.
    Schwartz MK
    Ann Clin Lab Sci; 1977; 7(2):99-104. PubMed ID: 322572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival markers related to bone metastases in prostate cancer.
    Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
    Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
    Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
    Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.